FLT3 and acute myeloid leukemia: Lack of study of physicochemical properties and in vivo properties such as safety profile, anti-apoptotic activity, and effect of long-term treatment on FLT3 AML cases; resulted in a poor application and hampered additional investigations and improvements for those azaindole-based FLT3 inhibitors.